CLEARWATER, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical") the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the pricing of its previously announced underwritten public offering of 2,762,431 shares of its common stock at a public offering price of $3.62 per share of common stock, before deducting underwriting discounts and commissions and offering expenses.

Lucid Capital Markets is acting as the sole book-running manager for the offering.

All of the shares of common stock to be sold in the offering will be sold by the Company. In addition, the Company has granted the underwriter a 45-day option to purchase up to an additional 414,365 shares of its common stock at the public offering price less the underwriting discounts and commissions. The offering is expected to close on or about November 19, 2025, subject to customary closing conditions.

The Company intends to use net proceeds from this offering for working capital and general corporate purposes. The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-268532) filed with the Securities and Exchange Commission ("SEC") on November 22, 2022, and declared effective by the SEC on December 2, 2022.

A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC's website at www.sec.gov. A final prospectus supplement will be filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus relating to the offering, when available, may also be obtained by contacting Lucid Capital Markets, LLC, 570 Lexington Avenue, 40th Floor, New York, NY 10022.

This press release shall ...